-+ 0.00%
-+ 0.00%
-+ 0.00%

Artiva Biotherapeutics To Highlight Cost-Effectiveness Of AlloNK In Community Rheumatology Practice And Continued Durability Of AlloNK In Non-Hodgkin Lymphoma At 2026 Tandem Meetings

Benzinga·01/21/2026 13:04:32
Listen to the news

Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) (Artiva), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with devastating autoimmune diseases and cancers, today announced presentations at the 2026 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR (Tandem Meetings) from February 4 – 7, 2026, in Salt Lake City, Utah highlighting the cost-effectiveness of AlloNK in a community rheumatology practice and continued durability of AlloNK in Non-Hodgkin Lymphoma (NHL).